Daniel H Solomon DanielHSolomon
7 years 2 months ago
Can a Nice Doctor Make Treatments More Effective? - The New York Times https://t.co/Aj5vUBofHJ
Dr. John Cush RheumNow
7 years 2 months ago
My advice to Patients on Joint Replacement Surgey: 1) talk to others who had the surgery; 2) consult orthopedics LONG before its urgent; 3) PRE-hab (getting strong before surgery); 4) Get a physical therapist who will work you to normal (3-5X/wk for 4-8 wks)
Dr. John Cush RheumNow
7 years 2 months ago
Measures used to limit costs & utilization of expensive biologics: 1) Generics 1st requirement; 2) Pre-authorization; 3) limited (6-9 mos) approval w/ proof of benefit; 4) 30 day supply; 5) preferred tiered drugs; & 6) utilize less expensive providers https://t.co/2HRrJn87AY
Dr. John Cush RheumNow
7 years 2 months ago
2nd Edition of my "The War on RA" - being fought daily by rheumatologists - Change, Innovation and Discovery will be driven by Rheumatologists. Rheums must lead the fight to win the immense challenge of #RA today. We need you! https://t.co/7vOzRvvuVi
Dr. John Cush RheumNow
7 years 2 months ago
MMP-7 levels studied in myositis pts w/ anti-synthetase syndr (ARS) and fourd to be higher in ARS Ab+ & MDA5 Ab+ PM/DM-ILD patients, and were associated with a worse prognosis. MMP-7 levels associated w/ worse survival (OR 18.0). https://t.co/lGlc5S00sR
Dr. John Cush RheumNow
7 years 2 months ago
IL-18 may be a biomarker for Systemic JIA (Stills), higher w/ active dz and hx of MAS. Study of 40 sJIA pts finds elevated IL-18 levels inactive and active dz & with history of MAS. IL-18 was correlated w/ ferritin (R=0.74), CXCL9 (R=0.56), S100 (R=0.47) https://t.co/c0KjAyiEjq
Dr. John Cush RheumNow
7 years 2 months ago
70 #gout pts studied & 44.3% developed post-surgical flares. Risk factors included Presurgical sUA ≥ 9 mg/dL (OR 3.77) & sUA changes before and after surgery (OR 1.62); but \allopurinol reduced risk (OR 0.15). Mean time to flare=3.7 days. Knee > MTP1 https://t.co/U6rl5c8Cf3
A population-based claims study from Taiwan shows significantly increased incidences of depressive disorder, anxiety disorder, and sleep disorder in patients with primary Sjögren’s syndrome (pSS).
Dr. Jack Cush reviews the journal articles and news reports from the past week on RheumNow.com:
MMP-7 and Myositis-ILD; Post-surgical gout attacks; CV events and testosterone; and a Boxed warning for tofacitinib.
Dr. John Cush RheumNow
7 years 2 months ago
Candian study of 376 pregnancies (284 F) with #SLE and drug use: only 24.2% on antimalarials, 8.2% azathioprine, 19.7% steroids & 4.8% on NSAIDs during pregnancy. 1st trimester discontinuations seen in 16.7% of HCQ & 29.2% AZA https://t.co/YoRUXU9RJB
Psoriasis confers a significant risk of comorbidity, but is psoriasis associated with increased coronary inflammation and is this risk attenuated by biologic therapy?
JAMA Cardiology has published a cohort study of 134 consecutive patients with moderate to severe psoriasis, showing that biologic therapy was associated with a significant decrease in coronary inflammation as assessed by perivascular fat attenuation index, a marker of coronary
Dr. John Cush RheumNow
7 years 2 months ago
Phase IIb/III trial of multidoses of fasinumab (NGF mAb) in 421 pts w/ mod‐severe hip or knee #OA (WOMAC pain ~6+) showed signif reductions in pain (LMS -1.1 to -1.4) vs PBO (-.79) & >30% improved pain by @wk16 (63–74 vs 47%); arthropathy 7% FAS vs 1%PBO https://t.co/UtkqDE5lGf
Dr. John Cush RheumNow
7 years 2 months ago
RA patients with an inadequate response to adalimumab, in the presence of sufficient/high ADA drug levels, benefit 33% less from switching to another TNF inhibitor, etanercept. Data 449 RA patients in the Reade Rheumatology Registry https://t.co/uBzF8D9KpA
